Antigens Underlying Immunity References
  Whole Cells and Cell Extracts
  CandidiasisStrain CA2,live-attenuatedT-helper 1,cell-mediated immunity1,2
Genetically engineered Candida albicans tet-NRG1 strain,live-attenuatedT-cell mediated immunity3
Ribosomal Cell fractionAntibodies and cell-mediated immunity4,5
Inactivated whole cellsUndefined6
Hyr1pCell mediated immunity7
  BlastomycosisStrain BAD1,live-attenuatedT-helper 1,cell-mediated immunity8
  CoccidiomycosisInactivated spherulesT-helper 1,cell-mediated immunity9,10
Thimerosal-inactivated spherules (T27K)Undefined11
Genetically engineered strain,live-attenuatedT-helper 1,T-helper 2,cell-mediated immunity12
heat-killed Saccharomyces cerevisiae (HKY)Undefined13
  AspergillosisInactivated ConidiaUndefined14
Live attenuated conidiaUndefined14
  HistoplasmosisRibosomal VaccineUndefined15
  CoccidiomycosisMore than one geneUndefined16
  Paracoccidiomycosisgp43 geneT-helper 1,T-helper 2,cell-mediated immunity17
HSP65 DNAT-helper 118
  PneumocystosisKexin geneCell-mediated immunity and antibodies19
  Antigen-pulsed cells and T cells
  CandidiasisDendritic cell loaded with candida antigensT-helper 1,cell-mediated immunity1,20,21
  Aspergillus antigen-specific T cellsDendritic cell loaded with candida antigensT-helper 1,cell-mediated immunity1,20,22
  CoccidioimycosisDendritic cell based vaccineUndefined23
  Subunit and glycoconjugates
  CandidiasisAgglutinin-like sequencesCell-mediated immunity24
ecm33 mutant (RML2U)Undefined25,26
Secreated aspartic proteinase2Anti-Sap2 antibodies27
65 kDa mannoproteinAdhesin-neutralizing antibodies28
Beta-1,3-glucanCell-mediated immunity29,30
Beta-1,2-mannosidesAntibodies(opsonophagocytic;possibly adherence-blocking)31,32
CR3-RP glycoconjugateCell-mediated immunity33
  CryptococcosisCapsular polysaccharidesVarious mechanisms34
Glucuronoxylomannan-conjugated vaccineUnknown,possibly antibodies34
  AspergillosisAspergillus fumigatus antigensCell-mediated immunity22,35
Beta-1,3-glucanGrowth inhibitors,antibodies36
  CoccidiomycosisAntigen2Cell-mediated immunity,T-helper 137
Chimeric polyproteinUndefined9,39
  PneumocystosisP55 protein(major surface glycoprotein)Undefined,possibly antibodies40
Kexin proteaseCell-mediated immunity and antibodies19
  Paracoccidiomycosis43 kDa glycoproteinCell-mediated immunity and antibodies17
HSP60Cell-mediated immunity41
  Idiotypes and mimotopes
  CandidiasisKiller toxin neutralising mAbKT4Fungicidal antibodies42,43,44
  AspergillosisKiller toxin neutralising mAbKT4Fungicidal antibodies45
  CryptococcosisGlucuronoxylomannan-peptide mimotopesAntibodies modulating cell-mediated immunity46
P13 peptide mimotope-protein conjugatesT-helper 1,T-helper 2,cell-mediated immunity47
  CandidiasisMycograb,anti-Hsp90 peptideUnknown48,49
Anti-CA IgYInhibition of adhesion to host cells50
Anti-beta-1,3-glucan mAb 2G8Growth-inhibitory30,29
mAb C7(stress mannoprotein)Candidacidal51
Single chain fragment variable of anti-idiotypic antibodiesCandidacidal antibodies45
Anti-mannan mAb C6Opsonophagocytic31,32
Anti-glycosyl mAbCandidacidal52
Anti-Sap2 and anti-MP65domain antibodiesEnzyme and adhesion neutralizing53
  CryptococcosisSingle chain fragment variableInhibits glucan synthase54
Anti-glucuronoxylomannan 18B7-mAb(murine)Opsonophagocytic55
Anti-glucuronoxylomannan IgG2-mAb(human)Opsonophagocytic56
  HistoplasmosisAntibody against histone-like proteinUndefined57
  Synthetic, recombinant and conjugate vaccines
CoccidioidomycosisRecombinant Ag2/PRA106 + CSA chimeric fusion protein (CFP) vaccineCell-mediated immunity59
Recombinant proline-rich antigen (rAg2/Pra)T cell-mediated immunity60
  ParacoccidiomycosisAntigenic protein (rPb27)Cell-mediated immunity and antibodies61

1. Bozza S, Montagnoli C, Gaziano R, Rossi G, Nkwanyuo G, Bellocchio S, Romani L.Dendritic cell-based vaccination against opportunistic fungi.Vaccine. 2004 Feb 17;22(7):857-64.

2. Bistoni F, Vecchiarelli A, Cenci E, Puccetti P, Marconi P, Cassone A.Evidence for macrophage-mediated protection against lethal Candida albicans infection.Infect Immun. 1986 Feb;51(2):668-74.

3.Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL.Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis.Clin Vaccine Immunol. 2009 Mar;16(3):430-2. Epub 2009 Jan 14.

4.Segal E, Elad D. Fungal vaccines and immunotherapy.J Mycolog Med 2006; 16:134–51.

5. Levy DA, Bohbot JM, Catalan F, et al. Phase II study of D,651, an oral vaccine designed to prevent recurrences of vulvovaginal candidiasis. Vaccine 1989; 7:337–40.

6.Cardenas-Freitag L, Cheng E, Mayeux P, Domer JE, Clemens JD. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect Immun 1999; 67: 826–33.

7. Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, Fu Y.Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target.J Infect Dis. 2010 Jun 1;201(11):1718-28.

8. Wuthrich M, Chang W-L, Klein BS. Immunogenicity and protective efficacy of the WI-1 adhesin of Blastomyce dermatitidis. Infect Immun 1998; 66: 5443–49.

9. Cole GT, Xue J, Okee E, et al. A vaccine against coccidioidomycosis is justified and attainable. Med Mycol 2004; 42: 189–216.

10. Papagiannis D. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis 1993; 148: 656–60.

11. Lunetta JM, Simmons KA, Johnson SM, Pappagianis D.Molecular cloning and expression of a cDNA encoding a Coccidioides posadasii 1,2-alpha-mannosidase identified in the coccidioidal T27K vaccine by immunoproteomic methods.Ann N Y Acad Sci. 2007 Sep;1111:164-80. Epub 2007 Mar 15.

12. Xue J, Chen X, Selby D, Hung CY, Yu JJ, Cole GT.A genetically engineered live attenuated vaccine of Coccidioides posadasii protects BALB/c mice against coccidioidomycosis.Infect Immun. 2009 Aug;77(8):3196-208. Epub 2009 Jun 1.

13. Capilla J, Clemons KV, Liu M, Levine HB, Stevens DA.Saccharomyces cerevisiae as a vaccine against coccidioidomycosis.Vaccine. 2009 Jun 2;27(27):3662-8. Epub 2009 Apr 2.

14. Feldmesser M. Prospects of vaccines for invasive aspergillosis. Med Mycol 2005; 3: 571–87.

15. Deepe GS Jr, Wuthrich M, Klein BS. Progress in vaccination for histoplasmosis and blastomycosis: coping with cellular immunity.Med Mycol 2005; 43: 381–89.

16. Ivey FD, Magee DM, Woitaske MD, Johnston SA, Cox RA.Identifi cation of protective antigen of Coccidioides immitis by expression library immunization. Vaccine 2003; 21: 4359–67.

17. Pinto AR, Puccia R, Diniz SR, Franco MF, Travassos LR. DNA-based vaccination against murine paracoccidioidomycosis using the gp43 gene from Paracoccidioides brasiliensis. Vaccine 2000; 18: 3050–58.

18. Ribeiro AM, Bocca AL, Amaral AC, Souza AC, Faccioli LH, Coelho-Castelo AA, Figueiredo F, Silva CL, Felipe MS.HSP65 DNA as therapeutic strategy to treat experimental paracoccidioidomycosis.Vaccine. 2010 Feb 10;28(6):1528-34. Epub 2009 Dec 31.

19. Zheng M, Ramsay AJ, Robichaux MB, et al. CD4 T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 2005; 115: 3536–44.

20 Perruccio K, Bozza S, Montagnoli C, et al. Prospects for dendritic cell vaccination against fungal infections in hematopoietic transplantation. Blood Cells Mol Dis 2004; 33: 248–55.

21. Bacci A, Montagnoli C, Perruccio K, et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J Immunol 2002; 168: 2904–13.

22. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis.J Immunol 2000; 165: 381–88.

23. Awasthi S.Dendritic cell-based vaccine against coccidioides infection.Ann N Y Acad Sci. 2007 Sep;1111:269-74. Epub 2007 Mar 15.

24. Ibrahim AS, Spellberg BJ, Avanesian V, Fu Y, Edwards JE. The anti-candida vaccine based on recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis. Infect Immun 2006; 74: 3039–41.

25. Spellberg BJ, Ibrahim AS, Avanesian V, et al. Efficacy of the anti-candida rAls3p-N or Als1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis 2006; 194: 256–60.

26. Martínez-López R, Nombela C, Diez-Orejas R, Monteoliva L, Gil C.Immunoproteomic analysis of the protective response obtained from vaccination with Candida albicans ecm33 cell wall mutant in mice.Proteomics. 2008 Jul;8(13):2651-64.

27. Cassone A, Boccanera M, Adriani D, Dantoni G, De Bernardis F. Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun 1995; 63: 2619–24.

28. Sandini S, La Valle R, De Bernardis F, Macrì C, Cassone A. The 65 kDa mannoprotein gene of Candida albicans encodes a putative beta-glucanase adhesin required for hyphal morphogenesis and experimental pathogenicity. Cell Microbiol 2007; 9: 1223–38.

29. Torosantucci A, Bromuro C, Chiani P, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 2005; 202: 597–606.

30. Cassone A, Torosantucci A. Opportunistic fungi and fungal infections: the challenge of a single, general antifungal vaccine. Expert Rev Vaccines 2006; 5: 859–67.

31. Cutler JE. Defi ning criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 2005; 5: 383–92.

32. Han Y, Ulrich MA, Cutler JE. Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J Infect Dis 1999; 179: 1477–84.

33. Paulovicová E, Bystrický S, Machová E, Bujdáková H.Immune responsiveness of a novel peptidoglycan conjugate prepared from surface Candida immunogens: mannan and CR3-related protein.FEMS Immunol Med Microbiol. 2008 Aug;53(3):421-8. Epub 2008 Jul 10.

34. Oscarson S, Alpe M, Svahnberg P, Nakouzi A, Casadevall A.Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures. Vaccine 2005; 23: 3961–72.

35. Ito JI, Lyons JM, Hong TB et al. Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp13 protect mice against invasive aspergillosis. Infect Immun 2006; 74: 5075–84.

36. Luther K, Torosantucci A, Brakhage AA, Heeseman J, Ebel F. Phagocytosis of Aspergillus fumigatus conidia by murine macrophages involves recognition by detection β-glucan receptor and Toll-like receptor 2. Cell Microbiol 2007; 9: 368–81.

37. Cox RA, Magee DM. Coccidioidomycosis: host response and vaccine development. Clin Microbiol Rev 2004; 17: 804–39.

38. Tarcha EJ, Basrur V, Hung CY, Gardner M, Cole GT. A recombinant aspartyl protease of Coccidioides posadasii induces protection against pulmonary coccidioidomycosis in mice. Infect Immun 2006; 74: 516–17.

39. Theus SA, Smulian AG, Steele P, Linke MJ, Walzer PD. Immunization with the major surface glycoprotein of Pneumocystiscarinii elicits a protective response. Vaccine 1998; 16: 1149–57.

40. Zheng M, Ramsay AJ, Robichaux MB, et al. CD4 T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 2005; 115: 3536–44.

41. de Bastos Ascenço Soares R, Gomez FJ, de Almeida Soares CM, Deepe GS Jr.Vaccination with heat shock protein 60 induces a protective immune response against experimental Paracoccidioides brasiliensis pulmonary infection.Infect Immun. 2008 Sep;76(9):4214-21. Epub 2008 Jul 14.

42. Polonelli L, Lorenzini R, De Bernardis F, et al. Idiotypic vaccination: immunoprotection mediated by anti-idiotypic antibodies with antibiotic activity. Scand J Immunol 1993; 37: 105–10.

43. Polonelli L, De Bernardis F, Conti S, et al. Idiotypic intravaginal vaccination to protect against candidal vaginitis by secretory yeast killer toxin-like anti-idiotype antibodies. J Immunol 1994; 152: 3175–82.

44. Magliani W, Conti S, Salati A, et al. Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr Med Chem 2004; 11: 1793–800.

45. Datta K, Pirofski L. Toward a vaccine for Cryptococcus neoformans: principles and caveats. FEMS Yeast Res 2006; 6: 525–36.

46. Maitta RW, Datta K, Lees A, Belouski SS, Pirofski LA.Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.Infect Immun. 2004 Jan;72(1):196-208.

47. Matthews RC, Rigg G, Hodgetts S, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47: 2208–16.

48. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blind, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat-shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404–13.

49. Cassone A, Conti S, De Bernardis F, Polonelli L. Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature? Immunol Today 1997; 18: 164–69.

50. Ibrahim el-SM, Rahman AK, Isoda R, Umeda K, Van Sa N, Kodama Y.In vitro and in vivo effectiveness of egg yolk antibody against Candida albicans (anti-CA IgY).Vaccine. 2008 Apr 16;26(17):2073-80. Epub 2008 Mar 13.

51. Moragues MD, Omaxtebarria MJ, Elguezabal MJ, et al. A monoclonal antibody directed against Candida albicans cell wall mannoprotein exerts three anti-C albicans activities. Infect Immun 2003; 71: 5273–79.

52. Kawishwar A, Shukla PK. Candidacidal activity of a monoclonal antibody that binds with glycosyl moieties of proteins of Candida albicans. Med Mycol 2006; 44: 159–67.

53. De Bernardis F, Liu H, O’Mahony R, et al. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 2006; 195: 149–57.

54. Selvakumar D, Karim N, Miyamoto M, Furuichi Y, Komiyama T. Recombinant single chain anti-idiotypic antibody: an eff ective fungal β-1-3 glucan synthase inhibitor. Biol Pharm Bull 2006;29: 1848–53.

55. Larsen RA, Pappas PG, Perfect J, et al. Phase 1 evaluation of safetyand pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 2005; 49: 952–58.

56. Beenhover DO, Yoo EM, Lai CW, Rocha MA, Morrison SL. Human immunoglobulin G2 (IgG2) and IgG4 but not IgG1 or IgG3 protect mice against Cryptococcus neoformans infection. Infect Immun 2007; 75: 1424–35.

57. Nosanchuk JD, Steenbergen JN, Shi L, Deepe GS, Casadevall A. Antibodies to a cell surface histone-like protein protect against Histoplasma capsulatum. J Clin Invest 2003; 112: 1164

58. Xin H, Dziadek S, Bundle DR, Cutler JE.Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis.Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13526-31. Epub 2008 Aug 25.

59. Johnson SM, Lerche NW, Pappagianis D, Yee JL, Galgiani JN, Hector RF.Safety, antigenicity, and efficacy of a recombinant coccidioidomycosis vaccine in cynomolgus macaques (Macaca fascicularis).Ann N Y Acad Sci. 2007 Sep;1111:290-300. Epub 2007 Mar 8.

60. Herr RA, Hung CY, Cole GT.Evaluation of two homologous proline-rich proteins of Coccidioides posadasii as candidate vaccines against coccidioidomycosis.Infect Immun. 2007 Dec;75(12):5777-87. Epub 2007 Sep 17.

61. Reis BS, Fernandes VC, Martins EM, Serakides R, Goes AM.Protective immunity induced by rPb27 of Paracoccidioides brasiliensis.Vaccine. 2008 Oct 9;2 (43):5461-9. Epub 2008 Aug 21.